Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-58M

41M

Müük

-61M

711M

P/E

Sektori keskmine

51.957

64.641

Aktsiakasum

1.06

Dividenditootlus

0.25

Kasumimarginaal

5.726

Töötajad

11,000

EBITDA

-38M

180M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-5.15% downside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.25%

2.31%

Järgmine tulemuste avaldamine

4. aug 2026

Järgmine dividendimakse kuupäev

7. aug 2026

Järgmine aktsia dividendi kuupäev (ex-date)

23. okt 2026

Turustatistika

By TradingEconomics

Turukapital

2.4B

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

16%

84%

29 / 340 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:44 UTC

News

Revvity Inc shares are higher ahead of tomorrow's earnings report, with analysts projecting a 3.9% revenue growth year-on-year, recovering from last year's decline.

31. juuli 2026, 19:16 UTC

Revvity Inc shares are lower today amid broader market declines, influenced by rising yields and inflation concerns following a significant increase in crude oil prices.

29. juuli 2026, 20:08 UTC

Revvity Inc shares are higher today, reflecting a steady upward trend amid rising oil prices and broader market influences. The stock is near its one-month range high.

28. juuli 2026, 20:03 UTC

Revvity Inc shares are higher during Tuesday's session, continuing their advance since Monday's close, despite broader market weakness in Asian indices.

27. juuli 2026, 21:02 UTC

Revvity Inc shares are lower in after-market hours, continuing a downward trend with three consecutive daily declines. No specific news was identified for the movement.

22. juuli 2026, 18:51 UTC

Revvity Inc shares are higher since Tuesday's close amid broader market gains, influenced by rising crude oil prices from geopolitical tensions involving the U.S. and Iran.

21. juuli 2026, 20:02 UTC

Revvity Inc shares are higher, supported by renewed interest in AI stocks and anticipation of earnings from major companies like Alphabet and Tesla.

20. juuli 2026, 19:21 UTC

News

Revvity Inc. published its 2026 Impact Report, disclosing Scope 3 emissions. Shares are lower amid broader industry challenges and a cautious analyst outlook.

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

-5.15% langus

12 kuu keskmine prognoos

Keskmine 109.29 USD  -5.15%

Kõrge 130 USD

Madal 90 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

3

Osta

8

Hoia

0

Müü

Sentiment

By Acuity

29 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat